TITLE

Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series

AUTHOR(S)
Roohipoor, Ramak; Ghasemi, Hamed; Ghassemi, Fariba; Karkhaneh, Reza; Riazi-Esfahani, Mohammad; Nili-Ahmadabadi, Mehdi
PUB. DATE
September 2011
SOURCE
Graefe's Archive of Clinical & Experimental Ophthalmology;Sep2011, Vol. 249 Issue 9, p1295
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: To evaluate the results of intravitreal bevacizumab in terms of regression of retinopathy of prematurity (ROP). Methods: In this interventional case series, 12 eyes from January 2007 to December 2008 were included. Two groups of patients were considered. Group 1 included those ROP patients who did not respond to conventional laser therapy within 3 weeks or had some complications (hyphema or vitreous hemorrhage) after conventional laser therapy; intravitreal injection (0.625 mg) was performed as an adjuvant therapy. Group 2 included those with aggressive posterior ROP who received single intravitreal bevacizumab injection as the initial treatment. Results: Ten eyes of 12 patients with mean gestational age of 28.5 (range: 26-32) weeks and birth weight of 1,218 grams (range: 900-1,630) were included in the study. Mean conceptional age at the time of first visit was 40 weeks (30-48 weeks). All the patients had a history of supplemental oxygen. Eight patients (26.3%) were under mechanical ventilation. Eight eyes received bevacizumab after conventional laser therapy (group 1). Four eyes received intravitreal bevacizumab as the initial therapy (group 2). All of the patients were followed up for at least 1 year. All patients in group 1 responded to this adjuvant (intravitreal bevacizumab) treatment within 1 week, but two eyes of group 2 needed laser therapy 1.5 month after intravitreal bevacizumab injection in spite of the initial treatment response. No complications such as cataract, endophthalmitis or retinal detachment occurred. Conclusions: The use of intravitreal bevacizumab injection in premature eyes was well-tolerated, and induced prompt regression as an adjuvant therapy after conventional laser therapy and also as an alternative therapy in the management of aggressive retinopathy of prematurity.
ACCESSION #
65020372

 

Related Articles

  • Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Nazari, Hossein; Modarres, Mehdi; Parvaresh, Mohammad; Ghasemi Falavarjani, Khalil // Graefe's Archive of Clinical & Experimental Ophthalmology;Dec2010, Vol. 248 Issue 12, p1713 

    Purpose: To evaluate outcomes of intravitreal injection of bevacizumab for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhages (VH or RH). Methods: This is a prospective interventional case-series. Fourteen eyes of eight premature infants with...

  • Early Experience with Intravitreal Bevacizumab Combined with Laser Treatment for Retinopathy of Prematurity. Ahmed, Ayesha E.; Channa, Roomasa; Durrani, Jibran; Ali, Azam; Ahmad, Khabir // Middle East African Journal of Ophthalmology;Jul-Sep2010, Vol. 17 Issue 3, p264 

    Objective: This study was designed to present our early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity (ROP) at a single institution over a 13-month-period. Methods: A retrospective case series of eight children with ROP who received...

  • Bevacizumab.  // Reactions Weekly;7/17/2010, Issue 1310, p14 

    The article describes the case of a male infant who developed retinal detachment after receiving bevacizumab for retinopathy of prematurity.

  • Cataract surgery a success in adult ROP. Yashar, Alyson G.; Trese, Michael T. // Ophthalmology Times;2/1/98, Vol. 23 Issue 3, p20 

    Focuses on the study conducted by Michael T. Trese of Royal Oak, Michigan on the treatment of retinopathy of prematurity (ROP) in adult patients. Significance of the study findings; Background information on the problem caused by vitreoretinal interface.

  • Tratamiento de la retinopatía del prematuro con bevacizumab intravítreo. BANCALARI M., ALDO; SCHADE Y., RICARDO; PEÑA Z., RUBÉN; PAVEZ P., NICOLÁS // Revista Chilena de Pediatría;may/jun2013, Vol. 84 Issue 3, p300 

    Introduction: Standard treatment of threshold Retinopathy of Prematurity (ROP) is laser photocoagulation (LPC). Recently, bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor has been used with positive results. Objective: To communicate the response to treatment with bevacizumab...

  • Intravitreal injection of bevacizumab for retinopathy of prematurity. Kuniyoshi, Kazuki; Sugioka, Koji; Sakuramoto, Hiroyuki; Kusaka, Shunji; Wada, Norihisa; Shimomura, Yoshikazu // Japanese Journal of Ophthalmology;May2014, Vol. 58 Issue 3, p237 

    Purpose: To evaluate the outcomes of intravitreal injection of bevacizumab (IVB) for retinopathy of prematurity (ROP). Methods: IVB was selected to be the first treatment for type 1 ROP in 8 eyes (4 patients). Bevacizumab (0.25 mg/eye) was injected into the vitreous cavity under either general...

  • Intravitreal bevacizumab for stage 3+ retinopathy of prematurity.  // Africa Health;May2011, Vol. 33 Issue 4, p65 

    The article reports on the randomized clinical trial which compares the therapeutic effectiveness of using intravitreal bevacizumab for stage 3+ retinopathy of prematurity against the conventional laser therapy.

  • A Clinical Guide to Retinopathy of Prematurity. Lyon, Don W.; Warren, Danielle F. // Review of Optometry;12/15/2006, Vol. 143 Issue 12, p53 

    The article presents information on the diagnosis and treatment of retinopathy of prematurity (ROP). According to a National Eye Institute report, ROP is one of the leading causes of vision loss in children. ROP is caused in premature low birth weight infants. Once ROP is treated, long-term...

  • Anti-VEGFs may be viable option in treating retinopathy of prematurity. Cimberle, Michela // Ocular Surgery News;9/10/2009, Vol. 27 Issue 17, p29 

    The article reports on the claim of Georges Caputo of Fondation Rothschild about the potential of anti-vascular endothelial growth factor (VEGF) therapy in the treatment of retinopathy of prematurity (ROP). Caputo noted that VEGF is involved in the metabolic and inflammatory processes that lead...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics